Compare MLGO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLGO | LPCN |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.5M | 61.8M |
| IPO Year | N/A | N/A |
| Metric | MLGO | LPCN |
|---|---|---|
| Price | $4.04 | $8.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 176.6K | 109.4K |
| Earning Date | 09-10-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.04 | N/A |
| Revenue | ★ $61,302,336.00 | $4,322,693.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.70 | $2.52 |
| 52 Week High | $972.00 | $12.37 |
| Indicator | MLGO | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 52.92 |
| Support Level | $3.80 | $8.35 |
| Resistance Level | $4.83 | $9.15 |
| Average True Range (ATR) | 0.38 | 0.73 |
| MACD | -0.03 | -0.23 |
| Stochastic Oscillator | 12.50 | 33.29 |
MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.